Showing results (61-70 of 132) with videos related to

Sort By:
Pageof 14
Targeted Oncology|October 26, 2017
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced CancerZev A Wainberg, Maria Alsina, Heloisa P Soares, et al.
European Journal of Cancer (Oxford, England : 1990)|August 23, 2020
Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)Yung-Jue Bang, Talia Golan, Laetitia Dahan, et al.
Nature Medicine|November 9, 2010
Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistanceHiroshi Tanaka, Evelyn Kono, Chau P Tran, et al.
Molecular Cancer Therapeutics|July 28, 2021
Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid TumorsMichael S Gordon, John Nemunaitis, Minal Barve, et al.
ACS Nano|December 12, 2018
Improved Efficacy and Reduced Toxicity Using a Custom-Designed Irinotecan-Delivering Silicasome for Orthotopic Colon CancerXiangsheng Liu, Jinhong Jiang, Ryan Chan, et al.
The Oncologist|August 20, 2020
Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I StudyJohanna Bendell, Sunil Sharma, Manish R Patel, et al.
The Oncologist|December 4, 2020
Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric CancerStefano Cascinu, György Bodoky, Kei Muro, et al.
Cancer Discovery|March 1, 2017
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic CancersJohann de Bono, Ramesh K Ramanathan, Lida Mina, et al.
Nature Medicine|August 12, 2025
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final resultsZev A Wainberg, Colin D Weekes, Muhammad Furqan, et al.
British Journal of Cancer|July 16, 2019
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trialZachary W Veitch, David W Cescon, Trisha Denny, et al.
Pageof 14